Clinical Utility of Cognistat in Multiprofessional Team Evaluations of Patients with Cognitive Impairment in Swedish Primary Care

Table 1

Descriptive data (mean ± standard deviation (SD)) for the cognitive impairment group and the no cognitive impairment group after the final diagnoses.

Variables	Cognitive impairment; (𝑛=46)	No cognitive impairment; (𝑛=33)	𝑃 value
Females/males	22/24	25/8	0.013
Age, years ± SD	79±5.2	75±5.5	0.004
Education, years ± SD	9.7±3.6	11.5±3.9	0.037
Native language, 𝑛 (%)
Swedish	42 (91)	33 (100)	0.136^∗
Non-Swedish	4 (9)	0 (0)
Duration of cognitive symptoms, years ± SD	2.4±1.9	0.3±0.8	<0.001
Range	1–9	0–4
Medical history, 𝑛 (%)
Cerebrovascular disease	5 (11)	1 (3)	0.392^∗
Ischemic heart disease	15 (33)	5 (15)	0.078
Hypertension	30 (65)	17 (52)	0.221
Diabetic disease	7 (15)	1 (3)	0.130^∗
Anxiety	4 (9)	0 (0)	0.136^∗
Mild depression	6 (13)	1 (3)	0.229^∗
Medical drugs, 𝑛 (%)
Warfarin	7 (15)	4 (12)	0.754^∗
Salicylic acid (low dose)	25 (54)	10 (30)	0.034
Lipid-lowering drug	25 (54)	10 (30)	0.034
Antihypertensive	38 (83)	18 (54)	0.007
Insulin	4 (9)	0 (0)	0.136^∗
Antidiabetic	3 (7)	1 (3)	0.636^∗
Antidepressant	18 (39)	7 (21)	0.091
Sleeping drug	16 (35)	5 (15)	0.051
Antipsychotic	4 (9)	0 (0)	0.136^∗
Anxiolytic	11 (24)	4 (12)	0.188

𝑃 value analysed by 𝑡-test for age, education, and duration of symptoms. Chi-square and Fisher exact test∗ for native language, medical history, and medical drugs. Significant 𝑃 value <0.05.